East Sunshine drug second single anti-anti-drug attack targets Roche's $7.5 billion anti-tumor species

Pharmaceutical Network July 10, July 9, the latest data of CDE official website, East Sunshine Medicine's recombinant anti-VEGF monoclonal antibody injection clinical application was accepted, the product is Roche Beva zhussm mono-anti-injection biosimilar drugs, the current market has Qilu Pharmaceuticals, Cinda Bio two domestic enterprises approvedFigure 1: East Sunshine drug declaration of mono-resistant productsSource: CDE official website
CDE official website data show that East Sunshine medicine in January 2019 declared the reorganization of anti-TNF-alpha whole human-sourcemonoclonal antibody injection clinical application, and has been approved clinical, this is the second single anti-drug product declaration clinicalFigure 2: Sales of Roche Bevala beads mono-anti-injections (in millions of Swiss francs)Source: Minnet's cross-border listed companies sales database
Minet data show that Roche's Belaval Beads SLR Injections have seen a slow rise in global sales in recent years, reaching 7 billion Swiss francs (approximately US$7.5 billion) in 2019After entering the national health insurance negotiation directory in 2017, sales of the, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions) in China's publichospitals grew rapidly, with Roche's growth rate of 41% and 53% respectively in 2018-2019, and sales of the entire variety breaking through 3.4 billion yuan in 2019 after Qilu was approved to join the marketIn June 2020, Cinda Bio was also approved for listing, becoming the second company in ChinaSource: CDE official website, Minnet database
review data as of July 9, 2020, if there are any errors, please indicate